mstdn.science

Giuseppe Michieli<a href="https://mstdn.science/tags/Neutralization" class="mention hashtag" rel="tag">#Neutralization</a> and <a href="https://mstdn.science/tags/Stability" class="mention hashtag" rel="tag">#Stability</a> of <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="tag">#JN1</a>-derived <a href="https://mstdn.science/tags/LB1" class="mention hashtag" rel="tag">#LB1</a>, <a href="https://mstdn.science/tags/KP23" class="mention hashtag" rel="tag">#KP23</a>, <a href="https://mstdn.science/tags/KP3" class="mention hashtag" rel="tag">#KP3</a> and <a href="https://mstdn.science/tags/KP311" class="mention hashtag" rel="tag">#KP311</a> <a href="https://mstdn.science/tags/Subvariants" class="mention hashtag" rel="tag">#Subvariants</a> <a href="http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1" target="_blank" rel="nofollow noopener noreferrer" translate="no">http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1</a> We report on the neutralizing <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="tag">#antibody</a> (nAb) <a href="https://mstdn.science/tags/escape" class="mention hashtag" rel="tag">#escape</a>, infectivity, <a href="https://mstdn.science/tags/fusion" class="mention hashtag" rel="tag">#fusion</a>, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent <a href="https://mstdn.science/tags/mRNA" class="mention hashtag" rel="tag">#mRNA</a> <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a>, the <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

Giuseppe MichieliImmunogenicity and <a href="https://mstdn.science/tags/efficacy" class="mention hashtag" rel="tag">#efficacy</a> of <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> rS <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> against the <a href="https://mstdn.science/tags/EG51" class="mention hashtag" rel="tag">#EG51</a> <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="tag">#variant</a> of <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 in Syrian <a href="https://mstdn.science/tags/hamsters" class="mention hashtag" rel="tag">#hamsters</a>, J Virol.: <a href="https://journals.asm.org/doi/full/10.1128/jvi.00528-24?af=R" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://journals.asm.org/doi/full/10.1128/jvi.00528-24?af=R</a> Thus, based on these study results, the protein-based XBB.1.5 vaccine is immunogenic and increased the breadth of protection against the Omicron EG.5.1 variant in the Syrian hamster model.

Auscandoc“According to the federal government, 23 per cent of <a href="https://med-mastodon.com/tags/BritishColumbians" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BritishColumbians</a> have been vaccinated with the <a href="https://med-mastodon.com/tags/XBB15" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#XBB15</a> vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of <a href="https://med-mastodon.com/tags/BC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BC</a>.’s population, and that <a href="https://med-mastodon.com/tags/COVID" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID</a> strain is no longer dominant,”

Giuseppe Michieli<a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="tag">#BA4</a>/5 <a href="https://mstdn.science/tags/infection" class="mention hashtag" rel="tag">#infection</a> triggers more cross-reactive FcγRIIIa signaling and <a href="https://mstdn.science/tags/neutralization" class="mention hashtag" rel="tag">#neutralization</a> than <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="tag">#BA1</a>, in the context of <a href="https://mstdn.science/tags/hybrid" class="mention hashtag" rel="tag">#hybrid</a> <a href="https://mstdn.science/tags/immunity" class="mention hashtag" rel="tag">#immunity</a>, J Virol.: <a href="https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R</a> Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

Giuseppe Michieli<a href="https://mstdn.science/tags/Durability" class="mention hashtag" rel="tag">#Durability</a> of <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/Vaccines" class="mention hashtag" rel="tag">#Vaccines</a> against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="tag">#Omicron</a> <a href="https://mstdn.science/tags/Subvariants" class="mention hashtag" rel="tag">#Subvariants</a>, N Engl J Med.: <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2402779?query=TOC&cid=DM2342986_Non_Subscriber&bid=-1971795569" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.nejm.org/doi/full/10.1056/NEJMc2402779?query=TOC&cid=DM2342986_Non_Subscriber&bid=-1971795569</a> Overall, the XBB.1.5 vaccines were effective against omicron subvariants, although less so against <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="tag">#JN1</a>. Effectiveness was greater against <a href="https://mstdn.science/tags/hospitalization" class="mention hashtag" rel="tag">#hospitalization</a> and <a href="https://mstdn.science/tags/death" class="mention hashtag" rel="tag">#death</a> than against infection, and it waned moderately from its peak over time. The ramping and waning patterns were broadly similar to those of the bivalent boosters against BQ.1–BQ.1.1 and XBB–XBB.1.5.3

Giuseppe MichieliCharacteristics of <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="tag">#JN1</a>-derived <a href="https://mstdn.science/tags/SarsCoV2" class="mention hashtag" rel="tag">#SarsCoV2</a> <a href="https://mstdn.science/tags/subvariants" class="mention hashtag" rel="tag">#subvariants</a> <a href="https://mstdn.science/tags/SLip" class="mention hashtag" rel="tag">#SLip</a>, <a href="https://mstdn.science/tags/FLiRT" class="mention hashtag" rel="tag">#FLiRT</a>, and <a href="https://mstdn.science/tags/KP2" class="mention hashtag" rel="tag">#KP2</a> in neutralization <a href="https://mstdn.science/tags/escape" class="mention hashtag" rel="tag">#escape</a>, <a href="https://mstdn.science/tags/infectivity" class="mention hashtag" rel="tag">#infectivity</a> and membrane <a href="https://mstdn.science/tags/fusion" class="mention hashtag" rel="tag">#fusion</a> <a href="http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1" target="_blank" rel="nofollow noopener noreferrer" translate="no">http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1</a> Interestingly, <a href="https://mstdn.science/tags/antibodies" class="mention hashtag" rel="tag">#antibodies</a> in <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

Giuseppe Michieli<a href="https://mstdn.science/tags/Virological" class="mention hashtag" rel="tag">#Virological</a> characteristics of the <a href="https://mstdn.science/tags/SarsCoV2" class="mention hashtag" rel="tag">#SarsCoV2</a> <a href="https://mstdn.science/tags/KP2" class="mention hashtag" rel="tag">#KP2</a> <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="tag">#variant</a> <a href="http://biorxiv.org/cgi/content/short/2024.04.24.590786v1?rss=1" target="_blank" rel="nofollow noopener noreferrer" translate="no">http://biorxiv.org/cgi/content/short/2024.04.24.590786v1?rss=1</a> Particularly, KP.2 shows the most significant <a href="https://mstdn.science/tags/resistance" class="mention hashtag" rel="tag">#resistance</a> to the <a href="https://mstdn.science/tags/sera" class="mention hashtag" rel="tag">#sera</a> of monovalent <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/vaccinee" class="mention hashtag" rel="tag">#vaccinee</a> without <a href="https://mstdn.science/tags/infection" class="mention hashtag" rel="tag">#infection</a> (3.1-fold) as well as those who with infection (1.8-fold). Altogether, these results suggest that the increased immune resistance ability of KP.2 partially contributes to the higher Re more than previous variants including JN.1.

Giuseppe MichieliEvaluating <a href="https://mstdn.science/tags/Humoral" class="mention hashtag" rel="tag">#Humoral</a> <a href="https://mstdn.science/tags/Immunity" class="mention hashtag" rel="tag">#Immunity</a> Elicited by <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> Monovalent <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="tag">#COVID19</a> <a href="https://mstdn.science/tags/Vaccine" class="mention hashtag" rel="tag">#Vaccine</a>, Emerg Infect Dis.: <a href="https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article</a> We report boosting of <a href="https://mstdn.science/tags/IgG" class="mention hashtag" rel="tag">#IgG</a> (2.1×), <a href="https://mstdn.science/tags/IgA" class="mention hashtag" rel="tag">#IgA</a> (1.5×), and total IgG/A/M (1.7×) targeting the <a href="https://mstdn.science/tags/spike" class="mention hashtag" rel="tag">#spike</a> receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), <a href="https://mstdn.science/tags/EG51" class="mention hashtag" rel="tag">#EG51</a> (10.5×), and <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="tag">#JN1</a> (4.7×) variants.

Giuseppe Michieli[Correspondence] <a href="https://mstdn.science/tags/Effectiveness" class="mention hashtag" rel="tag">#Effectiveness</a> of <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/vaccines" class="mention hashtag" rel="tag">#vaccines</a> and <a href="https://mstdn.science/tags/antiviral" class="mention hashtag" rel="tag">#antiviral</a> drugs against severe <a href="https://mstdn.science/tags/outcomes" class="mention hashtag" rel="tag">#outcomes</a> of <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="tag">#omicron</a> infection in the <a href="https://mstdn.science/tags/USA" class="mention hashtag" rel="tag">#USA</a> <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00150-6/fulltext?rss=yes" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00150-6/fulltext?rss=yes</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> monovalent <a href="https://mstdn.science/tags/mRNA" class="mention hashtag" rel="tag">#mRNA</a> <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> <a href="https://mstdn.science/tags/booster" class="mention hashtag" rel="tag">#booster</a> elicits robust neutralizing <a href="https://mstdn.science/tags/antibodies" class="mention hashtag" rel="tag">#antibodies</a> against <a href="https://mstdn.science/tags/XBB" class="mention hashtag" rel="tag">#XBB</a> subvariants and <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="tag">#JN1</a>, Cell Host Microbe: <a href="https://doi.org/10.1016/j.chom.2024.01.014" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://doi.org/10.1016/j.chom.2024.01.014</a>• An XBB.1.5 booster markedly enhanced neutralization of SARS-CoV-2, including JN.1 • An XBB.1.5 booster induced similar antibody titers to XBB infection • Omicron infection followed by XBB.1.5 booster yielded the highest antibody titers • Our findings supported recommendations for broad use of the updated XBB.1.5 booster

Giuseppe MichieliAltered <a href="https://mstdn.science/tags/receptor" class="mention hashtag" rel="tag">#receptor</a> <a href="https://mstdn.science/tags/binding" class="mention hashtag" rel="tag">#binding</a>, <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="tag">#antibody</a> <a href="https://mstdn.science/tags/evasion" class="mention hashtag" rel="tag">#evasion</a> and retention of T cell recognition by the <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/spike" class="mention hashtag" rel="tag">#spike</a> protein, Nat Commun.: <a href="https://www.nature.com/articles/s41467-024-46104-2" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.nature.com/articles/s41467-024-46104-2</a>-- while the XBB.1.5 <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="tag">#variant</a> has retained efficient human receptor binding and gained <a href="https://mstdn.science/tags/antigenic" class="mention hashtag" rel="tag">#antigenic</a> alterations, it remains susceptible to recognition by T cells induced via vaccination and previous infection.

Giuseppe Michieli{Research Letter} Adverse <a href="https://mstdn.science/tags/Events" class="mention hashtag" rel="tag">#Events</a> After <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> -Containing <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="tag">#COVID19</a> <a href="https://mstdn.science/tags/mRNA" class="mention hashtag" rel="tag">#mRNA</a> <a href="https://mstdn.science/tags/Vaccines" class="mention hashtag" rel="tag">#Vaccines</a>, JAMA: <a href="https://jamanetwork.com/journals/jama/fullarticle/2815787?guestAccessKey=0726a751-3d5a-4fe9-8684-8def4f77331a&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=022624&adv=000003602429" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://jamanetwork.com/journals/jama/fullarticle/2815787?guestAccessKey=0726a751-3d5a-4fe9-8684-8def4f77331a&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=022624&adv=000003602429</a>-- In a nationwide cohort of more than 1 million adults aged 65 years and older, no increased risk of 28 adverse events was observed following vaccination with a monovalent XBB.1.5-containing vaccine.

Giuseppe Michieli<a href="https://mstdn.science/tags/Virological" class="mention hashtag" rel="tag">#Virological</a> characteristics of the <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="tag">#Omicron</a> <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="tag">#variant</a>, Nat Commun.: <a href="https://www.nature.com/articles/s41467-024-45274-3" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.nature.com/articles/s41467-024-45274-3</a>-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that <a href="https://mstdn.science/tags/ORF8" class="mention hashtag" rel="tag">#ORF8</a> nonsense mutation of XBB.1.5 resulted in impairment of <a href="https://mstdn.science/tags/MHC" class="mention hashtag" rel="tag">#MHC</a> suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

Giuseppe MichieliLink-Gelles R, Ciesla AA, Mak J, et al. Early <a href="https://mstdn.science/tags/Estimates" class="mention hashtag" rel="tag">#Estimates</a> of Updated 2023–2024 (Monovalent <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a>) <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="tag">#COVID19</a> <a href="https://mstdn.science/tags/Vaccine" class="mention hashtag" rel="tag">#Vaccine</a> <a href="https://mstdn.science/tags/Effectiveness" class="mention hashtag" rel="tag">#Effectiveness</a> Against Symptomatic <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Infection" class="mention hashtag" rel="tag">#Infection</a> Attributable to Co-Circulating <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="tag">#Omicron</a> Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, <a href="https://mstdn.science/tags/USA" class="mention hashtag" rel="tag">#USA</a>, Sept 2023–Jan 2024. MMWR Morb Mortal Wkly Rep 2024;73:77–83. DOI: <a href="http://dx.doi.org/10.15585/mmwr.mm7304a2" target="_blank" rel="nofollow noopener noreferrer" translate="no">http://dx.doi.org/10.15585/mmwr.mm7304a2</a>

Giuseppe Michieli-- En relación con la <a href="https://mstdn.science/tags/Covid19" class="mention hashtag" rel="tag">#Covid19</a>, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres <a href="https://mstdn.science/tags/subvariantes" class="mention hashtag" rel="tag">#subvariantes</a> de <a href="https://mstdn.science/tags/%C3%93micron" class="mention hashtag" rel="tag">#Ómicron</a>: <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a>, <a href="https://mstdn.science/tags/XBB19" class="mention hashtag" rel="tag">#XBB19</a> y <a href="https://mstdn.science/tags/XBB116" class="mention hashtag" rel="tag">#XBB116</a>, clasificadas por la OMS como de interés o bajo vigilancia.

Giuseppe Michieli-- The significant increase in anti-S <a href="https://mstdn.science/tags/IgG" class="mention hashtag" rel="tag">#IgG</a>, expansion of diverse S-specific MBC populations, and enhanced neutralising responses position the updated <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> as a critical <a href="https://mstdn.science/tags/tool" class="mention hashtag" rel="tag">#tool</a> for enhancing <a href="https://mstdn.science/tags/protection" class="mention hashtag" rel="tag">#protection</a> in vulnerable populations against evolving <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/variants" class="mention hashtag" rel="tag">#variants</a>.

Giuseppe Michieli[Correspondence] Immune responses following <a href="https://mstdn.science/tags/BNT162b2" class="mention hashtag" rel="tag">#BNT162b2</a> <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> <a href="https://mstdn.science/tags/vaccination" class="mention hashtag" rel="tag">#vaccination</a> in patients on <a href="https://mstdn.science/tags/haemodialysis" class="mention hashtag" rel="tag">#haemodialysis</a> in <a href="https://mstdn.science/tags/Germany" class="mention hashtag" rel="tag">#Germany</a> <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00783-1/fulltext?rss=yes" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00783-1/fulltext?rss=yes</a>

Giuseppe Michieli-- These observations suggest that a single dose of <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> monovalent <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> potentially induces antiviral humoral <a href="https://mstdn.science/tags/immunity" class="mention hashtag" rel="tag">#immunity</a> against XBB subvariants as well as <a href="https://mstdn.science/tags/BA286" class="mention hashtag" rel="tag">#BA286</a> without previous infection.

Giuseppe Michieli[Correspondence] Antiviral humoral <a href="https://mstdn.science/tags/immunity" class="mention hashtag" rel="tag">#immunity</a> against <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="tag">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="tag">#omicron</a> <a href="https://mstdn.science/tags/subvariants" class="mention hashtag" rel="tag">#subvariants</a> induced by <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> monovalent <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> in <a href="https://mstdn.science/tags/infection" class="mention hashtag" rel="tag">#infection</a>-naive and XBB-infected individuals <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00784-3/fulltext?rss=yes" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00784-3/fulltext?rss=yes</a>

Giuseppe Michieli[Correspondence] Short-term <a href="https://mstdn.science/tags/effectiveness" class="mention hashtag" rel="tag">#effectiveness</a> of the <a href="https://mstdn.science/tags/XBB15" class="mention hashtag" rel="tag">#XBB15</a> updated <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="tag">#COVID19</a> <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="tag">#vaccine</a> against <a href="https://mstdn.science/tags/hospitalisation" class="mention hashtag" rel="tag">#hospitalisation</a> in <a href="https://mstdn.science/tags/Denmark" class="mention hashtag" rel="tag">#Denmark</a>: a national cohort study <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00746-6/fulltext?rss=yes" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00746-6/fulltext?rss=yes</a>-- In summary, early results from cohort analyses with natl health registry data in indicate a high level of protection from XBB.1.5 vaccine, at least in short term; vaccination was associated with a 76·1% reduced risk of COVID-19 hospitalisation in a population vaccinated with a booster dose the previous season.

Recent searches

Search options

Administered by:

Server stats:

#xbb15